Huons Co., Ltd. (KOSDAQ:243070)

Market Cap	417.13B +44.1%
Revenue (ttm)	620.77B +5.2%
Net Income	42.66B +44.8%
EPS	3,600.00 +51.6%
Shares Out	11.65M
PE Ratio	9.94
Forward PE	n/a
Dividend	920.00 (2.57%)
Ex-Dividend Date	May 26, 2026

Volume	75,147
Average Volume	128,190
Open	35,750
Previous Close	35,800
Day's Range	35,050 - 37,150
52-Week Range	24,550 - 41,500
Beta	0.14
RSI	65.29
Earnings Date	May 12, 2026

About Huons

Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1965
• Employees: 912
• Stock Exchange: KOSDAQ
• Ticker Symbol: 243070

Financial Performance

In 2025, Huons's revenue was 620.77 billion, an increase of 5.17% compared to the previous year's 590.23 billion. Earnings were 42.66 billion, an increase of 44.84%.